Market closed

Krystal Biotech/$KRYS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Ticker

$KRYS
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Pittsburgh, United States

Employees

229
Website
www.krystalbio.com

Krystal Biotech Metrics

BasicAdvanced
$4.3B
84.77
$1.77
0.82
-

$4.3B

0.82

$219.34

$107.50

278K

7.966

7.658

0.698

0.844

4.58%

6.38%

84.77

17.705

4.88

4.88

73.647

2,722.80%

-257.10%

-13.33%

What the Analysts think about Krystal Biotech

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.

Krystal Biotech Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Krystal Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Krystal Biotech News

AllArticlesVideos
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

GlobeNewsWire·17 hours ago
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Seeking Alpha·3 weeks ago
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KRYS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Krystal Biotech stock?

Krystal Biotech (KRYS) has a market cap of $4.3B as of January 15, 2025.

What is the P/E ratio for Krystal Biotech stock?

The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 84.77 as of January 15, 2025.

Does Krystal Biotech stock pay dividends?

No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Krystal Biotech dividend payment date?

Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.

What is the beta indicator for Krystal Biotech?

Krystal Biotech (KRYS) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.